Biotechnology major Biocon said it has inked a pact with Saudi Arabia-based drug firm Tabuk Pharmaceutical Manufacturing Company to commercialize select specialty products in the Middle East region. Tabuk Pharmaceutical Manufacturing Company is a fully owned subsidiary of Astra Industrial Group, a leading pharmaceutical company in the Middle East and North Africa (MENA) region. Under the terms of this agreement, Tabuk Pharmaceuticals will hold the marketing authorization for select specialty products of Biocon and be responsible to register, importing, and promoting them in Saudi Arabia and other Middle East countries. As part of the out-licensing deal with Tabuk, Biocon will develop and manufacture the products, and Tabuk will commercialize them, the biotechnology company.
The partnership will pave the way for Biocon’s expansion into the MENA region to include Saudi Arabia, UAE, Kuwait, Qatar, Oman, and Iraq, in addition to Jordan and Lebanon. As part of our role and mission at Tabuk Pharmaceuticals to deliver unique health solutions and enhance the well-being of people in Saudi Arabia and countries we operate in, our partnership with as distinguished and renowned a company as Biocon, comes in as an evident choice to further support our mission in line with Saudi Vision 2030. Tabuk Pharmaceuticals develops, manufactures, markets, and distributes various branded generics, in addition to manufacturing pharmaceutical products for international partners at its manufacturing sites in Saudi Arabia.